CPT-11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer
Open Access
- 1 September 1994
- journal article
- clinical trial
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 85 (9), 972-977
- https://doi.org/10.1111/j.1349-7006.1994.tb02977.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous InfusionJNCI Journal of the National Cancer Institute, 1992
- An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.Journal of Clinical Oncology, 1990
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989
- LIMITED SAMPLING MODELS FOR AMONAFIDE (NSC-308847) PHARMACOKINETICS1988
- Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in miceCancer Chemotherapy and Pharmacology, 1988
- IDENTIFICATION OF MAMMALIAN DNA TOPOISOMERASE-I AS AN INTRACELLULAR TARGET OF THE ANTICANCER DRUG CAMPTOTHECIN1988
- ANTITUMOR-ACTIVITY OF 7-ETHYL-10-[4-(1-PIPERIDINO)-1-PIPERIDINO]CARBONYLOXY-CAMPTOTHECIN, A NOVEL WATER-SOLUBLE DERIVATIVE OF CAMPTOTHECIN, AGAINST MURINE TUMORS1987
- PEDA: A microcomputer program for parameter estimation and dosage adjustment in clinical practice.Journal of Pharmacobio-Dynamics, 1987
- Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.Journal of Biological Chemistry, 1985
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981